

REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults

NCT07015905

Status	RECRUITING
Phase	Phase 3
Sponsor	Regeneron Pharmaceuticals
Enrollment	2,000 participants

Key Eligibility Criteria

Inclusion (3)

- Is undergoing a primary elective unilateral TKA
- Is in good health based on laboratory safety testing as described in the protocol
- Body weight ≥ 130 kg at screening visit as described in the protocol

Exclusion (5)

- Any condition that, as assessed by the investigator, may confound the results of the study or pose an additional risk to the participant by study participation
- History of bleeding in the 6 months prior to randomization requiring hospitalization or transfusion as described in the protocol
- History of thromboembolic disease or thrombophilia
- History of major surgery, including brain, spinal, or ocular, or major trauma within approximately the past 6 months prior to randomization
- Has an estimated Glomerular Filtration Rate (GFR) of < 30 mL/min/1.73 m² at the screening visit as described in the protocol

Locations (40 total)

Shoals Medical Trials, Inc., Sheffield, Alabama, United States
CARI Clinical Trials, Riverside, California, United States
Denver Metro Orthopedics, P.C. Englewood Location, Englewood, Colorado, United States
... and 37 more locations